Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.76 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.76 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7736074 | 1.00 | CDK1 (0.76) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL4762882 | 1.00 | CDK1 (0.76) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL914447 | 1.00 | CDK1 (0.76) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL4764191 | 1.00 | CDK1 (0.76) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL346869 | 1.00 | CDK1 (0.76) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL29524904 | 0.96 | CDK1 (0.83) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL875991 | 0.90 | CDK1 (0.66) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL2808642 | 0.89 | CDK1 (0.64) | CDK1CCNB1CA2CA9MEN1 | |
| SCHEMBL5081419 | 0.88 | CDK1 (0.61) | CDK1CCNB1CA2CA9MEN1 | |
| Raffinose SCHEMBL23549944 | 0.88 | CDK1 (0.97) | CDK1CCNB1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432470-B1 | — | — | None | — | — | US | claimed |
| US-6432470-B2 | BY INCORPORATING TREHALOSE INTO SUCROSE IN A GIVEN AMOUNT | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 2002-08-13 | — | — | US | claimed |
| WO-2018175879-A1 | METHODS OF TREATING LACTOSE INTOLERANCE AND IMPROVING GASTROINTESTINAL HEALTH | RITTER PHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| US-9808481-B2 | Prebiotic formulations and methods of use | RITTER PHARMACEUTICALS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9775860-B2 | Prebiotic formulations and methods of use | RITTER PHARMACEUTICALS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3202406-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | Ritter Pharmaceuticals, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170216328-A1 | METHODS AND COMPOSITIONS FOR MICROBIOME ALTERATION | RITTER PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9592248-B2 | Prebiotic formulations and methods of use | RITTER PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9579340-B2 | Prebiotic formulations and methods of use | RITTER PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-3125905-A1 | METHODS AND COMPOSITIONS FOR MICROBIOME ALTERATION | Ritter Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20160367579-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | RITTER PHARMACEUTICALS INC (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2400839-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | Ritter Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110287072-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | RITTER PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011137249-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | RITTER PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20110236480-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | RITTER PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110223248-A1 | METHODS AND COMPOSITIONS FOR TREATING LACTOSE INTOLERANCE | RITTER PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010098822-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | RITTER PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100215738-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | RITTER PHARMACEUTICALS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| EP-1427818-A2 | NUCLEIC ACID MOLECULES CODING FOR A DEXTRAN-SACCHARASE CATALYSING THE SYNTHESIS OF DEXTRAN WITH ALPHA 1,2-OSIDIC SIDECHAINS | Monsan, Pierre (FR) | 2004-06-16 | — | — | EP | disclosed |
| WO-2002074943-A2 | NUCLEIC ACID MOLECULES CODING FOR A DEXTRAN-SACCHARASE CATALYSING THE SYNTHESIS OF DEXTRAN WITH ALPHA 1,2-OSIDIC SIDECHAINS | CENTRE NATIONAL DE LA RECHERCE SCIENTIFIQUE (FR) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216328-A1 | METHODS AND COMPOSITIONS FOR MICROBIOME ALTERATION | SI, FABP2, MGAM | CDK1 4681/4885CCNB1 1852/4885CA2 1251/4885 |
| US-20100215738-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | LCT, SI, MGAM | CDK1 3305/4885CCNB1 2662/4885CA2 1133/4885 |
| US-20110236480-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | LCT, SI, MGAM | CDK1 3467/4885CCNB1 2771/4885CA2 1171/4885 |
| US-20110287072-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | LCT, SI, MGAM | CDK1 3467/4885CCNB1 2771/4885CA2 1171/4885 |
| US-20160367579-A1 | PREBIOTIC FORMULATIONS AND METHODS OF USE | LCT, SI, MGAM | CDK1 3305/4885CCNB1 2662/4885CA2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.